Krajina: Írsko
Jazyk: angličtina
Zdroj: HPRA (Health Products Regulatory Authority)
NALTREXONE HYDROCHLORIDE
Bristol-Myers Squibb Pharmaceuticals uc
N07BB04
NALTREXONE HYDROCHLORIDE
50mg Milligram
Tablets
Product subject to prescription which may not be renewed (A)
Drugs used in alcohol dependence
Authorised
2001-10-15
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT NALOREX ® 50 mg Film Coated Tablets (Naltrexone Hydrochloride) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Nalorex is and what it is used for 2. What you need to know before you take Nalorex 3. How to take Nalorex 4. Possible side effects 5. How to store Nalorex 6. Contents of the pack and other information 1. WHAT NALOREX IS AND WHAT IT IS USED FOR The name of your medicine is Nalorex. Nalorex contains the active ingredient naltrexone hydrochloride. Naltrexone hydrochloride belongs to a group of medicines called opioid antagonists. NALOREX is used together with other forms of treatment such as counselling to help you to remain free from your dependence on heroin, methadone and other similar opiate drugs of addiction. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE NALOREX DO NOT TAKE NALOREX IF YOU: • Have liver failure or hepatitis (inflammation of the liver) • Are currently dependent on opiate drugs or going through withdrawal • Are currently taking any medicines which contain any opioids which include certain cough medicines (e.g. mixtures containing dextromethorphan), analgesic pain killers (e.g. morphine, codeine) Prečítajte si celý dokument
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nalorex 50mg Film Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Naltrexone hydrochloride 50 mg per tablet. Excipients with known effect: lactose monohydrate, 204mg per tablet. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. (Tablet) Pale yellow, film-coated, capsule-shaped tablet, debossed on one side with ‘R11’ and scored and debossed with ‘50’ on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Nalorex is indicated as an adjunctive prophylactic therapy in the maintenance of detoxified, formerly opioid-dependent patients. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be considered only in patients who have remained opioid free for a minimum of 7 – 10 days and are not showing signs or symptoms of withdrawal. Self reported abstinence should be verfied by urinalysis. Administration of Nalorex must not be started before a naloxone challenge test is performed and a negative result obtained. The naloxone test is positive if signs or symptoms of withdrawal appear. A Naloxone hydrochloride challenge is recommended to minimise the chance of a prolonged withdrawal syndrome precipitated by Nalorex (see section 4.4). _Naloxone test_ Intravenous: Administer 0.2 mg naloxone IV. If no adverse reactions appear after 30 seconds, administer another dose of 0.6 mg naloxone iv. Continue observing the patient over 20 minutes for signs of withdrawal. Subcutaneous: Administer 0.8 mg naloxone subcutaneously. Observe the patient for 20 minutes for signs and symptoms of withdrawal. Confirmation of the test: If there is any doubt that the patient is opioid-free, treatment with Nalorex should be delayed 24 hours. In this case, the test should be Prečítajte si celý dokument